FDA Approved VIDAS®...
23rd October 2013 Content supplied by:
Parvovirus B19 R-gene® Kit Detects and Quantifies B19 Genotypes
The bioMérieux Parvovirus B19 R-gene® kit, is a new CE-marked ARGENE® real-time PCR test, used for the detection and quantification of the three Parvovirus B19 genotypes.
This new molecular diagnostic test, developed and produced at bioMérieux’s site in Verniolle (France), is part of the ARGENE® range of molecular biology tests, one of the most comprehensive ranges on the market for monitoring viral infections in immunocompromised patients. The Parvovirus B19 R-gene® kit is the only molecular diagnostic solution that enables detection and quantification of the three Parvovirus B19 genotypes with identical sensitivity, on various types of biological samples (whole blood, plasma and serum). It also enables qualitative detection in bone marrow and medullary plasma.
The Parvovirus B19 R-gene® kit can be used on the majority of nucleic acid extraction platforms on the market, including the bioMérieux NucliSENS® easyMag® system. Amplification and detection with the Parvovirus B19 R-gene® test can be carried out on the main real-time PCR platforms available in laboratories.
Date Published: 23rd October 2013
bioMérieux Announces U.S.
FDA Approved VIDAS® C. difficile